64 related articles for article (PubMed ID: 37244250)
1. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
[TBL] [Abstract][Full Text] [Related]
2. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract][Full Text] [Related]
3. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
Barbe R; Belkouchi Y; Menu Y; Cohen R; David C; Kind M; Harguem S; Dawi L; Hadchiti J; Selhane F; Billet N; Ammari S; Bertin A; Lawrance L; Cervantes B; Hollebecque A; Balleyguier C; Cournede PH; Talbot H; Lassau N; Andre T
Eur J Cancer; 2024 May; 202():114020. PubMed ID: 38502988
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
[TBL] [Abstract][Full Text] [Related]
5. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
[TBL] [Abstract][Full Text] [Related]
6. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.
Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
[TBL] [Abstract][Full Text] [Related]
7. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C; Auclin E; Alouani E; Mercier M; Hollebecque A; Turpin A; Mazard T; Pernot S; Dutherage M; Cohen R; Borg C; Hautefeuille V; Sclafani F; Ben-Abdelghani M; Aparicio T; De La Fouchardière C; Herve C; Perkins G; Heinrich K; Kunzmann V; Gallois C; Guimbaud R; Tougeron D; Taieb J
Br J Cancer; 2024 Feb; 130(3):442-449. PubMed ID: 38102227
[TBL] [Abstract][Full Text] [Related]
8. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M; Fernández-Martos C; Elez E; Foguet C; Pedrosa L; Rodríguez N; Ruiz-Casado A; Pineda E; Cid J; Cabezón R; Oliveres H; Lozano M; Ginés A; García-Criado A; Ayuso JR; Pagés M; Cuatrecasas M; Torres F; Thomson T; Cascante M; Benítez-Ribas D; Maurel J
Cancer Immunol Immunother; 2023 Apr; 72(4):827-840. PubMed ID: 36083313
[TBL] [Abstract][Full Text] [Related]
9. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
Viale G; Trapani D; Curigliano G
Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
[TBL] [Abstract][Full Text] [Related]
10. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
Bernard L; How JA; Patel S; Yates MS; Jazaeri A
Gynecol Oncol; 2024 Jan; 180():139-145. PubMed ID: 38091773
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Orhan A; Mørup S; Poulsen LØ; Pfeiffer P; Qvortrup C; Gögenur I
Ugeskr Laeger; 2023 Dec; 185(51):. PubMed ID: 38105736
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Ravn NH; Havsteen I; Eiberg JP; Meden P
Ugeskr Laeger; 2023 Dec; 185(51):. PubMed ID: 38105737
[TBL] [Abstract][Full Text] [Related]
13. Research Perspective on: Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair-Deficient Locally Advanced Colon Cancer: An Emerging Strategy.
Liska D
Dis Colon Rectum; 2024 Jun; 67(6):772. PubMed ID: 38452372
[No Abstract] [Full Text] [Related]
14. Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatment.
Mechahougui H; Friedlaender A
Immunotherapy; 2024 Mar; 16(5):267-271. PubMed ID: 38112055
[No Abstract] [Full Text] [Related]
15. Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.
Bou Farhat E; Adib E; Daou M; Naqash AR; Matulonis U; Ng K; Kwiatkowski DJ; Sholl LM; Nassar AH
Cancer Cell; 2024 Feb; 42(2):323. PubMed ID: 38350424
[No Abstract] [Full Text] [Related]
16. Aiming at different targets for immunotherapy.
Nat Cancer; 2023 Sep; 4(9):1211. PubMed ID: 37749356
[No Abstract] [Full Text] [Related]
17. Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal Intestinal-Type Adenocarcinoma: A Retrospective Study Supports the Adverse Prognostic Impact of Tumor Budding.
Puccio S; Azzarello G; Maffeis V; Laurino L; Mairani E; Conte F; Tessari N; Cazzador D; Zanoletti E; Politi D; Emanuelli E; Spinato G; Ausoni S
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791973
[TBL] [Abstract][Full Text] [Related]
18. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R
Front Immunol; 2024; 15():1352262. PubMed ID: 38361927
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Alouani E; Mercier M; Flecchia C; Auclin E; Hollebecque A; Mazard T; Turpin A; Pernot S; Cohen R; Dutherage M; Kim S; Sclafani F; Ben-Abdelghani M; Herve C; Aparicio T; De La Fouchardière C; Perkins G; Hautefeuille V; Jaffrelot M; Gallois C; Bongard V; Tougeron D; Taïeb J; Guimbaud R
ESMO Open; 2023 Jun; 8(3):101574. PubMed ID: 37244250
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]